HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: C500006-JLR200v1 46/7/1364    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Glass, M. Articles by Mitchell, M. D. Search for Related Content PubMed PubMed Citation Articles by Glass, M. Articles by Mitchell, M. D. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 46, 1364-1368, July 2005
Copyright © 2005 by American Society for Biochemistry and Molecular Biology

Rapid Communication

Misidentification of prostamides as prostaglandins

Michelle Glass^1,*, Jiwon Hong^*, Timothy A. Sato and Murray D. Mitchell^*,,

^* Department of Pharmacology, Auckland, New Zealand
Liggins Institute, Auckland, New Zealand
University of Auckland, and National Research Centre for Growth and Development, Auckland, New Zealand

Published, JLR Papers in Press, May 1, 2005. DOI 10.1194/jlr.C500006-JLR200

¹ To whom correspondence should be addressed. e-mail: m.glass{at}auckland.ac.nz

ABSTRACT

Prostaglandins and endogenous cannabinoid metabolites share the same lipid backbone with differing polar head groups at exactly the position through which a large molecule is attached to provide antigenicity and thus raise antisera. Hence, we hypothesized that antisera raised against prostaglandins linked to a large molecule such as BSA at the carboxyl functional group would also recognize endogenous cannabinoid metabolites and lead to highly misleading interpretations of data. We found major cross-reactivity of commercial antisera raised to prostaglandins with endocannabinoid metabolites. Furthermore, in a well-characterized cell line (WISH) or primary amnion tissue explants, endocannabinoid treatment led to increased production of endocannabinoid metabolites as opposed to primary prostaglandins. This was apparent only after separation of products by thin-layer chromatography, because they measured as prostaglandins by radioimmunoassay.

These findings have major implications for our interpretation of data in situations in which these prostaglandin-like molecules are formed, and they stress the need for chromatographic or spectrometric confirmation of prostaglandin production detected by antibody-based methods.

Supplementary key words ethanolamides • prostamides • endocannabinoids • anandamide

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. D. Mitchell, T. A. Sato, A. Wang, J. A. Keelan, A. P. Ponnampalam, and M. Glass Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E352 - E356. [Abstract] [Full Text] [PDF]

				S. F. E. Nilsson, E. Drecoll, E. Lutjen-Drecoll, C. B. Toris, A. H.-P. Krauss, A. Kharlamb, A. Nieves, T. Guerra, and D. F. Woodward The Prostanoid EP2 Receptor Agonist Butaprost Increases Uveoscleral Outflow in the Cynomolgus Monkey. Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 4042 - 4049. [Abstract] [Full Text] [PDF]